30 August 2012 Equity Focus

# Equity 1 00

#### **Key Data**

Share price (HK\$)	76.45
52Wk H/L(HK\$)	83.45 / 56.8
Issued shares (mn)	1,229
Market cap (HK\$mn)	93,959
30-day avg vol (HK\$mn)	163
Major shareholder (%):	
Sze Man Bok(Chairman)	18.62
Hui Lin Chit(CEO)	18.29

Source: Company, Bloomberg, ABCI Securities

#### Revenue composition in 1HFY12(%)

-	( )
Tissue papers	48.8
Sanitary napkins	25.0
Disposable diapers	14.6
Food and snacks	8.9
Others	2.7


Source: Company

Share performance (%)

	Absolute	Relative*
1-mth	2.0	(0.8)
3-mth	(0.3)	(5.9)
6-mth	6.5	15.9

Source: Bloomberg \*Relative to Hang Seng Index

### 1 year price performance



Source: Bloomberg

#### Analyst:

Name: Judy Hu Tel: (852) 2147 8310 Email: judyhu@abci.com.hk

Previous report:1 Aug Rating:Unrated

# Hengan (1044 HK) – Unrated Personal Products Industry

## Key takeaways from company visit

We met the management of Hengan this week. The group will boost its tissue papers sales in 2H as new production lines will commence operation in 2H. As raw material (pulp & petrochem) prices will maintain at 1H low level, we expect that its gross profit margin in 2H will maintain flat with 1H. However, its operating profit margin is expected lower than 1H FY12 due to more promotion and A&P expense.

**Impressive margin improvement:** Its 1H FY12 sales increased moderately by10.4%YoY to HK\$9,042mn (5% lower than consensus) due to weak sales growth of tissue papers segment and disposable diapers segment. Its sanitary napkins sales grew by 22.5%YoY in 1H FY12. Its net profit surged by 37.6%YoY to HK\$1,626mn in 1H FY12, 1.4% higher than consensus. Due to drop of raw material cost and increasing high margin products sales, its gross profit margin increased by 5.6ppt to 44.2% in 1H FY12 (vs 38.6% in 1H FY11). Its operating profit margin increased by 7.1ppt to 23.6% in 1H FY12% (vs 16.5% in 1H FY11).

**2H FY12 outlook:** The delayed tissue paper production lines will commence operation in the 2H, adding total capacity to 900,000 tons at the end of FY12 (36.7% increase from 660,000tons in 1HFY12). The group will increase promotion to boost tissue paper sales in 2H FY12. The management expects its tissue paper sales growth to exceed sanitary napkin sales growth in 2H FY12..

**Valuation:** The stock is trading at 27.2x PER for FY12, 12.3% lower than its past 5 years average PER of 31x.

**Risk:** Slower-than-expected sales growth in 2H; Intensified competition and promotion

### **Forecast and Valuation**

FY ended Dec 31	FY10A	FY11A	FY12E	FY13E	FY14E
Sales(HK\$ mn)	13,432	17,051	20,704	25,617	30,808
Chg (YoY)	24.0	26.9	21.4	23.7	20.3
Net Income (HK\$ mn)	2,438	2,649	3,438	4,261	5,045
Chg (YoY)	15.2	8.6	29.8	23.9	18.4
FD EPS (HK\$)	2.00	2.16	2.81	3.47	4.14
Chg (YoY)	12.8	8.2	29.9	23.7	19.2
DPS (HK\$)	8.58	10.04	11.01	12.51	14.28
NBV (HK\$)	1.30	1.35	1.77	2.16	2.50
PER (x)	-	35.4	27.2	22.0	18.5
P/B (x)	-	7.6	6.9	6.1	5.4
Dividend yield (%)	-	1.8	2.3	2.8	3.3
ROAA (%)	14.9	12.6	14.1	16.3	18.0
ROAE (%)	25.0	23.2	26.4	28.9	30.3

Source: Company, Bloomberg, ABCI Securities estimates



Exhibit1: 1H FY12 results review

(HK\$ mn)	1H11	1H12	YoY growth	HoH growth	Comments
Turnover	8,189	9,042	10.4%	2.0%	Sales growth was not good due to slower diaper and tissue paper growth
Sanitary napkins	1,848	2,265	22.5%	0.0%	
Disposable diapers	1,232	1,321	7.3%	(11.4%)	
Tissue paper	3,920	4,411	12.5%	7.6%	
Food and snacks	859	809	(5.8%)	18.4%	
Skin care products and others	330	236	(28.5%)	(27.1%)	
COGS	(5,029)	(5,043)	0.3%	(3.4%)	
Gross profit	3,160	3,999	26.5%	9.8%	
Other Income	82	185	-	-	
Distribution costs	(1,540)	(1,607)	4.4%	(3.8%)	
Administrative expenses	(352)	(439)	24.5%	10.1%	
Operating profit	1,349	2,138	58.5%	9.9%	Operating profit grew faster than sales growth due to improving gross profit margin and drop of SG&A / sales
Finance costs, net	65	(85)	-	-	
Profit before taxation	1,414	2,052	45.2)	11.5%	
Taxation	(206)	(411)	-	-	
Profit after taxation	1,207	1,642	36.0%	11.1%	
Minority interests	(26)	(15)	-	-	
Profit attributable to shareholders	1,182	1,626	37.6%	10.9%	
Gross profit margin	38.6%	44.2%	+5.6ppt	+3.12ppt	Improved by raw material cost decline
Operating profit margin	16.5%	23.6%	+7.1ppt	+1.66ppt	
Net profit margin	14.4%	18.0%	+3.6ppt	+1.45ppt	

Source: Bloomberg, ABCI Securities estimates



## **Disclosures**

### **Analyst Certification**

I, Hu Zhaoling, being the person primarily responsible for the content of this research report, in whole or in part, hereby certify that all of the views expressed in this report accurately reflect my personal view about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. I and/or my associates have no financial interests in relation to the listed company (ies) covered in this report, and I and/or my associates do not serve as officer(s) of the listed company (ies) covered in this report.

#### **Disclosure of Interests**

ABCI Securities Company Limited and/or its member companies ("ABCI") may pursue financial interests to the companies mentioned in the report."

#### Disclaimers

This report is for our clients only and is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expresses or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein. This report should not be regarded by recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas as a result of using different assumptions and criteria. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. ABCI Securities Company Limited is under no obligation to update or keep current the information contained herein. ABCI Securities Company Limited relies on information barriers to control the flow of information contained in one or more areas within ABCI Securities Company Limited, into other areas, units, groups or affiliates of ABCI Securities Company Limited. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of ABCI Securities Company Limited as a whole, of which investment banking, sales and trading are a part. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. The price and value of the investments referred to in this research and the income from them may fluctuate. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither ABCI Securities Company Limited nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. Additional information will be made available upon request.

### Copyright 2012 ABCI Securities Company Limited

No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of ABCI Securities Company Limited.

Office address: ABCI Securities Company Limited, 13/F Fairmont House, 8 Cotton Tree Drive, Central, Hong Kong.

Tel: (852) 2868 2183